A milestone Alzheimer's disease trial has seen a drug successfully slow down symptoms of the devastating condition.
Makers of an experimental drug have conducted a large trial in which the treatment slowed the decline in participants' memory and thinking. It is a rare win in research fighting a disease that slowly destroys cognitive function.
If approved by regulators, Lecanemab could be the first drug to directly target the disease rather than manage its symptoms. Alzheimer's Research UK has hailed the breakthrough as a "historic moment".
